The short version
- Why people research itAnabolism, muscle hyperplasia and recovery (advanced tool).
- What the evidence isNo randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
- What to watchShaking, sweating or confusion.
How IGF-LR3 works
Modified IGF-1 that resists binding proteins, so it stays active far longer than native IGF-1 — drives anabolism and hyperplasia.
The name says what was done to the molecule, and the market has read it as something else. Long R3 IGF-I is human IGF-I with two changes: arginine substituted at residue 3 in place of the native glutamate, and a 13-residue extension added to the N-terminus.
What the Arg3 substitution actually does. The N-terminal region of IGF-I contains the contact residues for the IGF-binding proteins, and Glu3 is one of them. Replace it with arginine — swapping a negative side chain for a positive one at a contact point — and the binding-protein interaction is destroyed while the receptor-binding face, which is elsewhere on the molecule, is left intact.
- Injectable
Research on IGF-LR35 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
No completed human trial
Correlative data
Recombinant IGF-1 itself (mecasermin) IS an approved human drug for severe primary IGF-1 deficiency, and its label is the most useful document here.
LR3 is a modified analog with far lower binding-protein affinity, so more of it circulates free and active. That does not make it last longer: in rats it is cleared from the circulation faster than native IGF-1, and its half-life in people has never been measured. Nothing about the human data on mecasermin transfers cleanly to it except the direction of the risk.
How the mechanism reads
The Long-Arg3 modification prevents IGF-binding-protein capture, so the peptide stays free instead of parked in the binding-protein reservoir. That is the whole design and it predicts both effects: much greater anabolic signaling per unit, and much greater hypoglycemia risk than native IGF-1.
MechanisticSustained IGF-1 receptor activation is also the mechanism behind the long-term concern nobody can resolve — IGF-1 signaling promotes proliferation indiscriminately, which is useful in muscle and unwelcome anywhere with an undiagnosed problem.
Mechanistic
Sources
- Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.. Biochem J 1992 · PMID 1371669
- Bastian SE, Walton PE, Wallace JC, Ballard FJ. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats.. J Endocrinol 1993 · PMID 7693845
- Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.. J Endocrinol 1995 · PMID 7561636
- Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.. J Endocrinol 1996 · PMID 8708565
- Bastian SE, Walton PE, Belford DA. Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats.. J Endocrinol 2000 · PMID 10607940
IGF-LR3 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Any cancer or precancerous lesion, since sustained IGF-1 receptor activation is mitogenic.
- Diabetes or low blood sugar on glucose-lowering drugs.
- Heavy fasting or endurance training with low fuel.
- Eye disease from diabetes, where IGF-1 signaling can worsen new vessel growth.
- Pregnancy or under 18, with no human safety record at all.
What’s expected
- Longer action than native IGF-1 because it evades binding proteins.
- Hypoglycemia risk from insulin-like action.
- Everything else is extrapolated from rodent work.
Watch for
- Shaking, sweating or confusion.
- Rapid growth of a mole or lump.
- Swelling of hands and face.
Labs that tell you it’s working
- IGF-1: may read low or odd, because the analog does not bind carrier proteins like the native peptide.
- Insulin (Fasting): suppressed endogenous insulin tells you the signal landed.
- Fructosamine: reads glucose swings over the past few weeks.
- Comprehensive Metabolic Panel: fasting glucose and liver enzymes.
Long R3 IGF-1 analog that resists IGFBP binding for prolonged potency; no human trial, so profile is inferred from IGF-1 receptor biology. PMID 7561636 PMID 1371669
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
IGF-LR3 FAQ4 common questions
- Is IGF-LR3 approved for human use?
- No. IGF-LR3 is a research compound. No completed randomized human trial has given it yet.
- What is IGF-LR3 researched for?
- Anabolism, muscle hyperplasia and recovery (advanced tool).
- Which labs show whether it's doing anything?
- IGF-1; Insulin; Fructosamine; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for IGF-LR3: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





